Literature DB >> 18761681

Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis.

Minoru Kobayashi1, Michihiro Suzuki, Hiroki Ikeda, Hideaki Takahashi, Nobuyuki Matsumoto, Shiro Maeyama, Shigeru Sase, Shiro Iino, Fumio Itoh.   

Abstract

AIM: The diagnosis of non-alcoholic steatohepatitis (NASH) can be difficult using blood tests and imaging studies. Histological diagnosis by liver biopsy remains the gold standard of NASH diagnosis. There is an urgent need to develop and validate simple, reproducible, noninvasive tests to accurately assess NASH stage and grade. We assess the usefulness of xenon computed tomography (Xe-CT), as a non-invasive method of quantitatively and visually determining hepatic tissue blood flows (TBFs), and xenon solubility (lambda value) simultaneously with TBF, in the evaluation of NASH pathophysiology.
METHODS: Histological severity of fatty changes and severity of fibrosis based on Brunt's classification were determined in 38 NASH patients. We evaluated correlations between the grade of fatty changes and lambda value, and correlations between the stage of fibrosis and TBFs.
RESULTS: The lambda value showed significant positive correlations with both grade of steatosis (r = 0.813, P < 0.001) and each 10% range of histological fatty infiltration (r = 0.926, P < 0.001). A significant negative correlation was seen between lambda value and the liver : spleen ratio (r = -0.835, P < 0.001). Portal venous tissue blood flow and total hepatic tissue blood flow showed significant negative correlations with the progression of fibrosis (r = -0.465, P < 0.01; r = -0.433, P < 0.01, respectively). Total hepatic tissue blood flow tended to decrease with progressing grade of steatosis.
CONCLUSION: Xe-CT offers a convenient and objective method for evaluating fatty infiltration and changes in blood flow in the entire liver, and appears useful for detailed evaluation of patients with NASH.

Entities:  

Year:  2008        PMID: 18761681     DOI: 10.1111/j.1872-034X.2008.00407.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

2.  Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function.

Authors:  Guobao Wang; Michael T Corwin; Kristin A Olson; Ramsey D Badawi; Souvik Sarkar
Journal:  Phys Med Biol       Date:  2018-07-24       Impact factor: 3.609

3.  Correlation between hepatic blood flow and liver function in alcoholic liver cirrhosis.

Authors:  Hideaki Takahashi; Ryuta Shigefuku; Yoshihito Yoshida; Hiroki Ikeda; Kotaro Matsunaga; Nobuyuki Matsumoto; Chiaki Okuse; Shigeru Sase; Fumio Itoh; Michihiro Suzuki
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 4.  X-ray-computed tomography contrast agents.

Authors:  Hrvoje Lusic; Mark W Grinstaff
Journal:  Chem Rev       Date:  2012-12-05       Impact factor: 60.622

5.  Xenon computed tomography can evaluate the improvement of hepatic hemodynamics before and after endoscopic injection sclerotherapy.

Authors:  Hideaki Takahashi; Michihiro Suzuki; Ryuta Shigefuku; Miki Okano; Tetsuya Hiraishi; Rei Takagi; Yohei Noguchi; Nobuhiro Hattori; Moriaki Hatsugai; Kazunari Nakahara; Masaru Okamoto; Minoru Kobayashi; Hiroki Ikeda; Yasunobu Fukuda; Yoshihiko Nagase; Toshiya Ishii; Kotaro Matsunaga; Nobuyuki Matsumoto; Chiaki Okuse; Shigeru Sase; Fumio Itoh
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

6.  Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?

Authors:  Ryuta Shigefuku; Hideaki Takahashi; Minoru Kobayashi; Hiroki Ikeda; Kotaro Matsunaga; Chiaki Okuse; Nobuyuki Matsumoto; Shiro Maeyama; Shigeru Sase; Michihiro Suzuki; Fumio Itoh
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

7.  Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma.

Authors:  Sang Soo Lee; Sook-Hyang Jeong; Young-Sang Byoun; Seong Min Chung; Mun Hyuk Seong; Hyung Rae Sohn; Bo-Young Min; Eun Sun Jang; Jin-Wook Kim; Guan Jung Park; Yoon Jin Lee; Kyoung Ho Lee; Soyeon Ahn
Journal:  BMC Cancer       Date:  2013-07-08       Impact factor: 4.430

8.  Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus.

Authors:  Ryuta Shigefuku; Hideaki Takahashi; Hiroyasu Nakano; Tsunamasa Watanabe; Kotaro Matsunaga; Nobuyuki Matsumoto; Masaki Kato; Ryo Morita; Yousuke Michikawa; Tomohiro Tamura; Tetsuya Hiraishi; Nobuhiro Hattori; Yohei Noguchi; Kazunari Nakahara; Hiroki Ikeda; Toshiya Ishii; Chiaki Okuse; Shigeru Sase; Fumio Itoh; Michihiro Suzuki
Journal:  Int J Mol Sci       Date:  2016-09-14       Impact factor: 5.923

9.  Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation.

Authors:  Tsuguru Hayashi; Tatsuyuki Watanabe; Michihiko Shibata; Shinsuke Kumei; Shinji Oe; Koichiro Miyagawa; Yuichi Honma; Masaru Harada
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

10.  Evaluation of hepatic tissue blood flow using xenon computed tomography with fibrosis progression in nonalcoholic fatty liver disease: comparison with chronic hepatitis C.

Authors:  Ryuta Shigefuku; Hideaki Takahashi; Masaki Kato; Yoshihito Yoshida; Keigo Suetani; Yohei Noguchi; Moriaki Hatsugai; Kazunari Nakahara; Hiroki Ikeda; Minoru Kobayashi; Kotaro Matsunaga; Nobuyuki Matsumoto; Chiaki Okuse; Fumio Itoh; Shiro Maeyama; Shigeru Sase; Michihiro Suzuki
Journal:  Int J Mol Sci       Date:  2014-01-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.